An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
pubmed:
26
10
2021
medline:
4
2
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
In recent years, a large number of articles have described the endocrine-related adverse events associated with immune checkpoint inhibitors, especially affecting the thyroid. A 37-year-old man affected by nasopharyngeal carcinoma (stage IVb) underwent serial 18F-FDG PET/CT evaluations during treatment with nivolumab (480 mg every 4 weeks) after first-line chemoradiotherapy. The patient had no history of thyroid disease and before starting immunotherapy the thyroid-stimulating hormone value was normal at 0.9 mU/L (reference range, 0.27-4.2 mIU/L). FDG PET/CT studies revealed involution of the thyroid gland following immune checkpoint inhibitor-induced thyroiditis.
Identifiants
pubmed: 34690289
doi: 10.1097/RLU.0000000000003946
pii: 00003072-202203000-00017
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Nivolumab
31YO63LBSN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253-254Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Ruggeri RM, Campennì A, Giuffrida G, et al. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest . 2019;42:745–756.
de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res . 2019;51:145–156.
Albano D, Treglia G, Giovanella L, et al. Detection of thyroiditis on PET/CT imaging: a systematic review. Hormones (Athens) . 2020;19:341–349.
Nobashi T, Baratto L, Reddy SA, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell–rich organs, and immune-related adverse events using FDG-PET/CT. Clin Nucl Med . 2019;44:e272–e279.
Marandino L, Capozza A, Bandini M, et al. Incidence and clinical impact of inflammatory fluorodeoxyglucose positron emission tomography uptake after neoadjuvant pembrolizumab in patients with organ-confined bladder cancer undergoing radical cystectomy [published online November 7, 2020]. Eur Urol Focus . 2020; S2405-4569(20)30287-X, doi: 10.1016/j.euf.2020.10.003.
doi: 10.1016/j.euf.2020.10.003
Kotwal A, Kottschade L, Ryder M. PD-L1 inhibitor–induced thyroiditis is associated with better overall survival in cancer patients. Thyroid . 2020;30:177–184.
Haupt F, Prosch H, Ebner L. Thyroid atrophy and pancreatic involution after cancer immunotherapy. Rofo . 2020;192:688–690.
Neppl C, Kaderli RM, Trepp R, et al. Histology of nivolumab-induced thyroiditis. Thyroid . 2018;28:1727–1728.